Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
3,649
Views
6
CrossRef citations to date
0
Altmetric
Articles

Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study

Peter Feng Wanga GSK, Upper Providence, PA, USACorrespondence[email protected]
View further author information
,
Christopher W. Yeeb Analysis Group, Inc., Boston, MA, USAView further author information
,
Boris Gorsha GSK, Upper Providence, PA, USAView further author information
,
Miriam L. Zichlinb Analysis Group, Inc., Boston, MA, USAView further author information
,
Prani Pakaa GSK, Upper Providence, PA, USAView further author information
,
Rachel H. Bhakb Analysis Group, Inc., Boston, MA, USAView further author information
,
Natalie Boytsova GSK, Upper Providence, PA, USAView further author information
,
Anamika Khanalb Analysis Group, Inc., Boston, MA, USAView further author information
,
Ahmed Nomanb Analysis Group, Inc., Boston, MA, USAView further author information
,
Maral DerSarkissianb Analysis Group, Inc., Boston, MA, USAView further author information
,
Shannon Ferrantea GSK, Upper Providence, PA, USAView further author information
&
Mei Sheng Duhb Analysis Group, Inc., Boston, MA, USAView further author information
 show all
Pages 398-406 | Received 13 Jun 2022, Accepted 15 Oct 2022, Published online: 21 Nov 2022

References

  • Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.
  • Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
  • Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet. 2009;374(9686):324–339.
  • Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373–383.
  • Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
  • van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.
  • Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):508–517.
  • Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol. 2017;112:153–170.
  • Lasiter L, Tymejczyk O, Garrett-Mayer E, et al. Real-world overall survival using oncology electronic health record data: friends of cancer research pilot. Clin Pharmacol Ther. 2022;111(2):444–454.
  • Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
  • Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107.
  • Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with >/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355–1361.
  • Braunlin M, Belani R, Buchanan J, et al. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 Oncology Clinic Electronic Health Record Data. Leuk Lymphoma. 2021;62(2):377–386.
  • Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376.
  • Kumar SK. Management of multiple myeloma. J Natl Compr Canc Netw. 2018;16(5S):624–627.
  • Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017–1025.
  • Oostvogels R, Jak M, Raymakers R, et al. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br J Haematol. 2018;183(1):60–67.
  • Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011;118(7):1763–1765.
  • Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160(5):649–659.
  • Nooka AK, Joseph NS, Kaufman JL, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019;125(17):2991–3000.
  • Garg AK. Community-based cancer care quality and expertise in a COVID-19 era and beyond. Am J Clin Oncol. 2020;43(8):537–538.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.